LRRK2 and Parkinson disease: Considering that pathogenic LRRK2 variants increase LRRK2 kinase activity, much research and clinical trials targeting LRRK2 have focused on reducing LRRK2 kinase activity and/or LRRK2 levels to treat both LRRK2 PD and iPD [10,61,62].